Eli Lilly’s market capitalization briefly exceeded $1 trillion as sales of GLP‑1 obesity and diabetes medicines propelled the company to a new valuation milestone. The surge underscores the commercial power of incretin therapies and invites market competition and policy scrutiny. At the same time, services and platforms such as Waltz Health announced direct‑to‑employer programs to negotiate access to high‑cost obesity medications from Novo Nordisk and Eli Lilly, signaling new commercialization channels for GLP‑1s and payer‑provider workarounds.